Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Pfizer Acquires Seagen with an Investment of US$43 Billion

Tuesday, March 14, 2023

Pfizer and Seagen announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US$229 in cash per Seagen share for a total enterprise value of US$43 billion.

Together, Pfizer and Seagen will accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer’s capabilities and expertise.

The addition of Seagen’s world-leading ADC technology makes its position at the forefront of innovative cancer care, and strongly complements the existing portfolio across both solid tumours and haematologic malignancies.

The combination of teams, and respective areas of strength and global footprints will allow to realise Seagen’s potential and advance even more potential breakthroughs to patients with cancer.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024